NCT06276634Recruiting
Intermittent Hypoxia in Persons With Multiple Sclerosis
Intermittent Hypoxia Initiated Motor Plasticity in Individuals With Multiple Sclerosis
Source: ClinicalTrials.gov · Last updated 20 Mar 2026
Brief summary (registry, in English)
This study aims to understand the mechanisms of a novel intervention involving breathing short durations of low levels of oxygen for persons with multiple sclerosis (MS). This intervention with low levels of oxygen is called Acute Intermittent Hypoxia (AIH), the levels of oxygen experienced are similar to breathing the air on a tall mountain, for less than 1 minute at a time. Previous studies have shown that AIH is a safe and effective way to increase strength in persons with MS. Here the investigators aim to look at brain activation and ankle strength before and after AIH to gain a better understanding of how the AIH may improve strength in those persons with MS.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 21 (estimated)
- First submitted
- 11 Dec 2023
- Start date
- 30 Apr 2024
- Primary completion date
- 3 Nov 2025
- Lead sponsor
- Shirley Ryan AbilityLab
- Diseases
- Multiple sclerosis
- NCT number
- NCT06276634
What you commit to
- Study type: Interventional
- Planned participants: 21
- From 30 Apr 2024 to the primary completion date, 3 Nov 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Active contrast-enhancing MS lesions, or diffusion positive lesions suggestive of acute cerebrovascular disease on baseline MRI scan
- Uncontrolled hypertension (Systolic between 85 and 140, diastolic between 90 and 55)
- History of epilepsy
- Chronic obstructive pulmonary disease
Other
- Uncontrolled Sleep apnea
- Pregnancy
Who the study is looking for
- Diagnoses of relapsing form of MS (including relapsing-remitting MS and secondary-progressive MS)
- Expanded Disability Status Scale (EDSS) score of at least 3 and no more than 6.5
- Motor Functional System Scale (FSS) between 2-4
- Relapse free for at least 1 year
- Age ≥ 18 years and ≤ 75 years
- Safe to be scanned based on MRI questionnaire
- Participants using dalfampridine will be eligible if taking the same daily dose for at least 2 months prior to screening
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Shirley Ryan AbilityLab Coordinator of this site? Confirm its status | Chicago | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.